Pharma BD Deal Intelligence
A total loss: Merck's ~$366M acquisition of NovaCardia bought Phase III heart-failure drug rolofylline, on which it had already written off $325M as in-process R&D. The drug failed its pivotal trial two years later with higher seizure and stroke rates than placebo, and was never approved.
Total loss: Merck's sole strategic rationale for NovaCardia — rolofylline — failed Phase III two years after close with worse safety than placebo, after Merck had already written off 89% of the deal value as acquired in-process R&D.
Full analysis, sources & comparables →Merck's $350M NovaCardia deal hands it a Phase 3 cardiorenal asset in KW-3902, a selective adenosine A1 antagonist with potential to differentiate from loop…
Rolofylline failed to beat placebo in the pivotal PROTECT trial and showed higher rates of seizures and stroke; Merck terminated development on September…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$350M + cash on hand (~$366M). KW-3902 Phase 3 acute heart failure. Source: Fierce Biotech, BioSpace, Contract Pharma.
Total loss: Merck's sole strategic rationale for NovaCardia — rolofylline — failed Phase III two years after close with worse safety than placebo, after Merck had already written off 89% of the deal value as acquired in-process R&D.
Assessment window: 15yr post-close.
978K US cases/yr
Acute decompensated heart failure (ADHF) drives roughly one million US hospitalizations a year and remains a leading cause of 30-day readmission and in-hospital mortality. A subset of ADHF patients develop worsening renal function on diuretics (cardiorenal syndrome), where standard loop diuretics lose efficacy and outcomes deteriorate sharply.
In 2007, ADHF inpatient pharmacotherapy was anchored on IV loop diuretics (furosemide, bumetanide, torsemide), vasodilators (nitroglycerin, nesiritide/Natrecor from Scios/J&J), and inotropes (milrinone, dobutamine), with Otsuka/Johnson & Johnson's tolvaptan (Samsca, V2 vasopressin antagonist) advancing through the EVEREST program. NovaCardia's KW-3902 (rolofylline), licensed from Kyowa Hakko Kirin, was a selective adenosine A1 receptor antagonist designed to preserve glomerular filtration and enhance diuresis without worsening renal function - a differentiated mechanism in the cardiorenal subset (Wikipedia; Merck/BioSpace, Sep 2007). Pilot Phase 3 data presented at the 2007 ESC Heart Failure Congress showed dyspnea improvement and renal-function protection vs. placebo, supporting Merck's $350M cash deal (Fierce Biotech, Jul 25 2007). The thesis collapsed when the pivotal PROTECT-1 trial reported in 2009 that rolofylline failed its primary endpoint and showed an excess of seizures and stroke; Merck terminated development on September 1, 2009 (Wikipedia). The deal is widely cited as a cautionary case in cardiovascular Phase 3 risk and informed Merck's later capital allocation away from CV bolt-ons.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / NovaCardia Inc. (this deal) | 2007 | $366M | 13 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2007 deals · Merck & Co. Inc. deals